Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Fungal Phylum Microsporidia01:28

Fungal Phylum Microsporidia

Microsporidia are a group of obligate intracellular fungi that were initially classified as protists but were later reclassified based on phylogenetic, molecular, and structural evidence linking them to the Chytridiomycota. These unicellular, non-motile organisms are highly specialized parasites that infect a wide range of animal hosts, including humans. They have evolved extensive genomic and metabolic reductions, making them highly dependent on their hosts for survival.Morphology and Genomic...
Healthcare Associated Infections II: Preventive Measures01:22

Healthcare Associated Infections II: Preventive Measures

Essential infection prevention measures are based on the knowledge of the infection chain, the modes of transmission in healthcare settings, and the use of the best practices in all healthcare settings. Compulsory public reporting of healthcare-associated infection rates is needed to allow individuals and the community to make informed choices regarding selecting a healthcare facility.
The best practices for preventing healthcare-associated infections include hand hygiene, patient risk...
Healthcare Associated Infections I: Iatrogenic, Exogenic and Endogenic01:26

Healthcare Associated Infections I: Iatrogenic, Exogenic and Endogenic

Healthcare-associated infections (HAIs) occur in a healthcare facility while a person receives care for another ailment. This category also includes work-related infections among healthcare staff.
HAIs significantly increase the cost of health care. Extended stays in healthcare institutions, increased disability, increased costs of medications, including specialized antibiotics, and prolonged recovery times add to the patient's expenses and the healthcare institution and funding bodies. Common...

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Fungal diagnostics and treatment in a UK children's hospital, 2019 - 2023: scope for stewardship.

Clinical microbiology and infection : the official publication of the European Society of Clinical Microbiology and Infectious Diseases·2026
Same author

Outcomes of invasive fungal infections in 358 children undergoing allogeneic haematopoietic stem cell transplantation: A prospective UK study.

British journal of haematology·2026
Same author

Clostridioides difficile infection in non-transplanted adults with haematological malignancy: Systematic review and meta-analysis on behalf of European Conference on Infections in Leukemia (ECIL) and Infectious Diseases Working Party (IDWP) of the European Society for Blood and Marrow Transplantation (EBMT).

Blood reviews·2026
Same author

Population pharmacokinetics and safety of continuous oxacillin in preterm and term neonates and infants.

Antimicrobial agents and chemotherapy·2026
Same author

Closing the gap on antifungal resistance.

Nature medicine·2026
Same author

Optimising COVID-19 episode identification using serology and PCR/rapid antigen testing: insights from the BRACE trial.

BMC infectious diseases·2026

Related Experiment Video

Updated: May 12, 2026

An Ex vivo Assay to Study Candida albicans Hyphal Morphogenesis in the Gastrointestinal Tract
07:42

An Ex vivo Assay to Study Candida albicans Hyphal Morphogenesis in the Gastrointestinal Tract

Published on: July 1, 2020

Invasive mold infections in the pediatric setting: current status and new developments.

Adilia Warris1,2, Pablo Rojo3, Andreas H Groll4

  • 1MRC Centre for Medical Mycology, Department of Biosciences, Faculty of Health and Life Sciences, University of Exeter, Exeter, UK.

Expert Review of Anti-Infective Therapy
|May 11, 2026
PubMed
Summary
This summary is machine-generated.

Invasive mold infections (IMIs) in children are serious. Isavuconazole offers a new treatment option, but more research is needed to confirm its effectiveness against other antifungals.

Keywords:
Childrenamphotericin Binvasive aspergillosisinvasive mold infectioninvasive mucormycosisisavuconazoleposaconazolevoriconazole

More Related Videos

Growing a Cystic Fibrosis-Relevant Polymicrobial Biofilm to Probe Community Phenotypes
03:53

Growing a Cystic Fibrosis-Relevant Polymicrobial Biofilm to Probe Community Phenotypes

Published on: April 19, 2024

Related Experiment Videos

Last Updated: May 12, 2026

An Ex vivo Assay to Study Candida albicans Hyphal Morphogenesis in the Gastrointestinal Tract
07:42

An Ex vivo Assay to Study Candida albicans Hyphal Morphogenesis in the Gastrointestinal Tract

Published on: July 1, 2020

Growing a Cystic Fibrosis-Relevant Polymicrobial Biofilm to Probe Community Phenotypes
03:53

Growing a Cystic Fibrosis-Relevant Polymicrobial Biofilm to Probe Community Phenotypes

Published on: April 19, 2024

Area of Science:

  • Pediatric Infectious Diseases
  • Mycology
  • Pharmacology

Background:

  • Invasive mold infections (IMIs) are a significant cause of illness and death in immunocompromised children.
  • Diagnosis and management of pediatric IMIs are challenging due to limited clinical trial data.

Purpose of the Study:

  • To review the epidemiology, diagnosis, and management of IMIs in pediatric patients.
  • To evaluate the role of isavuconazole, a newer triazole antifungal, in treating pediatric IMIs.

Main Methods:

  • Literature review of pediatric IMI epidemiology, diagnostics, and therapeutics.
  • Evaluation of isavuconazole's pharmacology, tolerability, and safety in pediatric patients.
  • Analysis of current and emerging treatment strategies for pediatric IMIs.

Main Results:

  • Current treatments include voriconazole, posaconazole, and liposomal amphotericin B.
  • Isavuconazole is approved and shows promise, with established safety and tolerability.
  • Management principles emphasize prompt treatment, diagnostics, source control, and supportive care.

Conclusions:

  • Isavuconazole is a valuable addition to the antifungal arsenal for pediatric IMIs.
  • Further large-cohort studies are necessary to define isavuconazole's comparative efficacy.
  • Novel antifungal agents are under development for rare mold infections.